Besides the enhanced suppression of tumor growth, the doxorubicin-containing liposomes conjugated to the GRP78-binding peptides substantially diminished CSC subpopulations in the breast cancer xenografts [224]; if so, these (or similar) peptide–liposome conjugates may become a potent weapon against breast cancer stemness. This evidence concerns the gene HSPA5 and breast carcinoma.